Calidi flags going-concern note in 2025 audit report for NYSE American disclosure

Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc.

CLDI

0.00
  • Calidi Biotherapeutics flagged that its 2025 Form 10-K audit report includes a going-concern explanatory paragraph.
  • The disclosure was issued to meet NYSE American Section 610(b) requirements.
  • The notice stated it does not reflect any change or amendment to the company’s 2025 filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605221800PRIMZONEFULLFEED9725533) on May 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.